Mizuho raised the firm’s price target on Revolution Medicines (RVMD) to $143 from $90 and keeps an Outperform rating on the shares following the company’s conference presentation. Revolution is positioned to become the “dominant leader” in pancreatic ductal adenocarcinoma with “best-in-class data” and a timeline that is two years ahead of competitors, the analyst tells investors in a research note. The firm cites the new zoldonrasib data for the target increase.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Merck Sees $70B Revenue Potential From New Growth Drivers by Mid-2030s
- Revolution Medicines: Dominant Pancreatic Cancer Position, Expanding RAS Franchise, and 2026 Catalyst Funnel Support Buy Rating
- $30B ‘might not be enough’ for Revolution Medicines, says Stifel
- Revolution Medicines CEO says not commenting on ‘rumors or speculation’
- Revolution Medicines CEO presenting at JPMorgan healthcare conference